drugset / Trial / NCT01119638

Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone

NCT01119638

Phase 4 Completed 40 enrolled Abarbanel Mental Health Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Behavioral and psychological symptoms of dementia (BPSD) are among the most distressing manifestations of dementia. Pharmacotherapy is frequently used and especially in institutional settings. Current guidelines recommend the use of second-generation antipsychotics (SGAs). Nonetheless, there are concerns regarding both their safety and effectiveness in patients with dementia. Inconclusive evidence support the use of other psychoactive agents such as SSRI antidepressants or cognitive enhancers. In two published studies citalopram was as efficacious as, but better tolerated than perphenazine or risperidone in patients with BPSD. Thus, with proven efficacy and a beneficial safety profile the evaluation of the use of escitalopram for BPSD is warranted.

Timeline

Start
2008-04
Primary completion
2010-04
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Escitalopram Small molecule 10 mg
Comparator Risperidone Other / unclassified 1 mg